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Epidermal growth factor receptor (EGFR)The G protein-coupled receptor kinases (GRKs) are best known for their role in phosphorylating and
desensitising G protein-coupled receptors (GPCRs). The GRKs also regulate signalling downstream of other fam-
ilies of receptors and have a number of non-receptor substrates and binding partners. Here we identify RhoAGTP
and Raf1 as novel binding partners of GRK2 and report a previously unsuspected function for this kinase. GRK2 is
a RhoA effector that serves as a RhoA-activated scaffold protein for the ERK MAP kinase cascade. The ability of
GRK2 to bind to Raf1, MEK1 and ERK2 is dependent on RhoAGTP binding to the catalytic domain of the kinase. Ex-
ogenous GRK2 has previously been shown to increase ERK activation downstreamof the epidermal growth factor
receptor (EGFR). Here we ﬁnd that GRK2-mediated ERK activation downstream of the EGFR is Rho-dependent
and that treatmentwith EGF promotes RhoAGTP binding and ERK scaffolding by GRK2. Depletion of GRK2 expres-
sion byRNAi reveals thatGRK2 is required for EGF-induced, Rho- and ERK-dependent thymidine incorporation in
vascular smoothmuscle cells (VSMCs). We therefore hypothesise that Rho-dependent ERKMAPK scaffolding by
GRK2 downstream of the EGFR may have an important role in the vasculature, where increased levels of both
GRK2 and RhoA have been associated with hypertension.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
The G protein-coupled receptor kinases (GRKs) are a family of seven
serine/threonine protein kinaseswith important and varied roles in reg-
ulating cellular signalling [1,2]. They are separated into 3 subfamilies
based on sequence homology. Both members of the GRK1 subfamily,
GRKs 1 and 7, are expressed in the retina and GRK1 is additionally
expressed in the pineal gland. The GRK2 subfamily, consisting of GRKs
2 and 3, and GRKs 5 and 6 of the GRK4 subfamily are widely expressed,
while GRK4 is found at signiﬁcant levels only in the testis, kidney and
cerebellum [3]. All the GRK family members share a highly conserved
central catalytic domain that is ﬂanked by a more variable amino-
terminal region and a poorly conserved, variable length carboxyl-
terminal region [1,2].DGKθ, diacylglycerol kinase θ;
in; GPCR, G protein-coupled re-
as-1; MAPK, mitogen-activated
et-derived growth factor; PI3K,
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.Open access under CC BY license. The classical function of the GRKs is to phosphorylate and desensitise
G protein-mediated signalling byGprotein-coupled receptors (GPCRs), a
family of approximately 800 cell-surface receptors with roles in regulat-
ing nearly all physiological processes. GRK2 is recruited to agonist
occupied GPCRs via its carboxyl-terminal pleckstrin-homology (PH) do-
main which binds to activated Gβγ subunits in the presence of
phosphatidylinositol-4,5-bisphosphate. Once bound to the activated
GPCR, GRK2 is allosterically activated and subsequently phosphorylates
the GPCR at serine and threonine residues usually within, either the
third intracellular loop, or carboxyl-terminal tail. This triggers β-
arrestin binding to the receptor, which prevents any further receptor-
dependent activation of heterotrimeric G proteins. β-arrestins then initi-
ate clathrin-coated pit-mediated receptor internalisation via recruitment
of a number of proteins, including the clathrin adaptor AP2 [1,3].
Although best known for regulating GPCR signalling, GRK2 has also
been implicated as a modulator of receptor tyrosine kinase (RTK) sig-
nalling [4]. In fact a number of parallels can be drawn between GPCR
and RTK signalling, including coupling of some RTKs to heterotrimeric
G proteins [5]. Akin to thewell-documented agonist-dependent recruit-
ment to GPCRs, GRK2 translocates to ligand-activated platelet-derived
growth factor (PDGF) and EGFRs and phosphorylates their intracellular
domains [6]. For the PDGF receptor, this results in reduced receptor ac-
tivation reminiscent of GRK2-mediated desensitisation of GPCRs [7].
However, while recruitment of GRK2 to the EGFR is Gβγ-dependent
[8], again reminiscent of its recruitment to GPCRs, this does not reduce
receptor activation [9]. In fact GRK2 recruitment to the EGFR positively
regulates EGF signalling, at least in terms of ERK activation [10,11].
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mediated by its phosphorylation of, and/or interactions with various
non-receptor substrates and binding partners [12]. For example, the
mitogen-activated protein kinase (MAPK) p38 is phosphorylated by
GRK2 [13], preventing its activation by the upstream kinase MAPKK6.
Phosphorylation of insulin receptor substrate-1 by GRK2 results in re-
duced insulin signalling [14], while GRK2-mediated phosphorylation
of SMADs 2 and 3, reduces transforming growth factor-β signalling
[15]. In contrast, M1muscarinic receptor-dependentmembrane rufﬂing
is positively regulated by GRK2-mediated phosphorylation of ezrin [16].
Akt is one example of many non-receptor binding partners for GRK2.
Binding to GRK2 inhibits the activation of Akt in sinusoidal endothelial
cells, resulting in reduced nitric oxide production by Akt-activated en-
dothelial nitric oxide synthase [17].
Given the importance of GPCRs in physiology, it is perhaps unsur-
prising that changes in the activity and/or expression levels of the
GRKs are associated with a number of different disease states. GRK2 is
particularly important in the pathology of cardiovascular diseases, in-
cluding hypertension [18] and heart failure [19]. The true complexity
of GRK2-mediated regulation of cellular signalling, for example at recep-
tors other than GPCRs and at levels downstream of receptors is, howev-
er, only recently becoming appreciated and suggests that the role of
GRK2 in these disease states may not be due simply to dysregulation
of GPCR signalling. Here we identify Raf1 and RhoGTP as novel GRK2
binding partners and demonstrate a new function for GRK2 as a scaffold
protein for the ERK MAP kinase cascade downstream of the EGFR. Im-
portantly, binding of GRK2 to RhoGTP is required for the scaffolding func-
tion of GRK2. GRK2 thus represents a previously unappreciated Rho
effector. GRK2 is required for Rho- andERK-dependent thymidine incor-
poration downstream of the EGFR in vascular smooth muscle cells
(VSMCs). We therefore hypothesise that this novel function of GRK2
as a Rho-activated ERK MAPK scaffold might have an important role in
the vasculature, where increased levels of both GRK2 and RhoA have
been associated with hypertension.
2. Materials and methods
2.1. Materials
Tissue culture dishes were obtained from Nunc, culture medium
from Gibco BRL, plasticware from Falcon or Sterilin and other reagents
from Sigma, unless otherwise stated. cDNAs: GRK5 (pRK5-GRK5) [20],
GRK2 (pRK5-GRK2) [20], GRK3 (pcDNA1-GRK3) [20], GST-CT (pEGB-
βARK-CT) [16], and GRK2-K220R (pBC12B1-βARK1-K220R) [16] were
gifts from Prof. R. Lefkowitz. GRK6A, B, C (pBK(Δ)-GRK6A, B, C) [20]
was from Dr. M. Tiberi. GRK2-NT (pEGFP-GRK2-(45-178)-GFP) [16]
was from Dr. R. Sterne-Marr. Flag-GRK2 (pcDNA3-GRK2-Flag), and
Flag-CAT (pcDNA3-GRK2-185-543-Flag) [21] were from Prof. Lan Ma.
GST (pGEX6p1-EV), GST-RhoA-V14 (pGEX6p1-RhoA-V14), RhoA-WT
(pRK5-MYC-RhoA-WT), RhoA-V14 (pRK5-MYC-RhoA-V14), RhoA-N19
(pRK5-MYC-RhoA-N19), RhoA-F25N (pRK5-MYC-RhoA-F25N) and
RhoA-V14/F25N (pRK5-MYC-RhoA-V14/F25N) [22] were from Dr. S.
Nurrish. Arf6-Q67L (pRK5-myc-Arf6-Q67L) [23], Rac-Q61L (pRK5-
myc-Rac-Q61L) [24], Cdc42-Q61L (pRK5-myc-Cdc42-Q61L) [24] and
Ras-V12 (pRK5-myc-Ras-G12V) [23] were from Prof. A. Hall. PTD-C3
(pGEX-KG-PTD-Myc-C3) [25] was from Prof. M. Olson. ERK2 (pEGFP-
C1-ERK2) was from Dr. R. Seger. MEK1 (pRK5-myc-MEK-1) and Raf-1
(pEGFP-Raf-1) [26] were from Dr. P. Rodriguez-Viciana. Others were
purchased from the Missouri S&T cDNA Resource Center. Antibodies
were sourced as follows: Anti-phospho-ERK (9401) from Cell Signaling
Technology. Anti-glutathione-s-transferase (GST) (27457701) from
Amersham. Anti-green ﬂuorescent protein (GFP) (11814460001) and
anti-HA (1867423) from Roche. Anti-ERK (M5670) and anti-Flag
(F3165) from Sigma. Anti-Myc (05-724) and anti-GRK4–6 (05-466)
from Millipore. Anti-GRK2 (SC-562), anti-MEK (SC-6250), anti-Raf
(SC-277), anti-PI3K (SC-7177) and anti-Gq (SC-393) from Santa CruzBiotechnology, Inc. C3 Rho inhibitor was produced as described by
Sahai and Olson [25].
2.2. COS, human embryonic kidney (HEK-293) and β-arrestin K/O mouse
embryonic ﬁbroblast (MEF) cell culture and transfection
Cells were cultured in Dulbecco's modiﬁed Eagle medium (DMEM)
containing 10% foetal calf serum (FCS) and penicillin (100 IU/ml)/strep-
tomycin (100 ug/ml) andweremaintained in a humidiﬁed incubator at
37 °C, with 5% CO2. Cells were transiently transfected using FuGENE HD
(Roche) according to manufacturer's instructions.
2.3. Co-immunoprecipitation
Cells in 9 cm dishes were transfected as indicated. 48 h later they
were washed twice with cold tris buffered saline (TBS) on ice and
lysed by addition of 1 ml cold GTPase lysis buffer (10% glycerol, 50 mM
Tris–HCl pH 8, 150 mM NaCl, 1% TX-100, 2 mM EDTA, 40 μg/ml PMSF,
1 mM benzamidine). After 15 s soniﬁcation, lysates were cleared by
centrifugation at 13,000 rpm for 5 min. Protein concentrations were de-
termined and volumes of lysates containing 200 μg protein were incu-
bated with 2 μg of the indicated antibody for 1 h at 4 °C on a rotating
platform. Protein A/G sepharose beads (GE Healthcare) were washed
in GTPase lysis buffer and 30 μl of a 50% suspension was added to each
sample before incubation for a further 1 h rotating at 4 °C. Beads were
washed 4 times in GTPase lysis buffer before adding 25 μl SDS reducing
buffer (25 mM Tris–HCl pH 6.5, 10% glycerol, 8% SDS, 5% β-
mercaptoethanol, containing Brilliant Blue G) to each sample ready for
analysis by SDS-PAGE. For quantiﬁcation of GRK2 fragment binding to
RhoA-V14, bands were quantiﬁed using Quantity One and the amount
of GRK2 co-immunoprecipitated per unit RhoA-V14 was plotted relative
to full length GRK2. For immunoprecipitation from EGF treated cells
(Figs. 4 and 5) the same protocol was used but cells were serum starved
for 24 h prior to EGF treatment and harvested in Buffer B (50 mM Tris
pH 7.2, 150 mM NaCl, 7.5 mM MgCl2, 1% TX-100, 40 μg/ml PMSF,
1 mM benzamidine, 100 μM Na3VO4, 10 mM β-glycerol phosphate,
20 mM NaF, 10 mM NaPPi). Immunoprecipitations were performed as
described above using Buffer B throughout.
2.4. Direct binding assay
Full length GRK2 or GRK2 catalytic domain was in vitro translated
using the Promega quick-coupled transcription/translation system
according to the manufacturer's instructions. 10 μl of the in vitro trans-
lation product was then incubated with 10 μg puriﬁed GST or GST-
RhoA-V14 on glutathione sepharose beads (GE Healthcare) in 200 μl
IVT buffer (50 mM Tris pH 7.5, 100 mM NaCl, 10 mM MgCl2, 0.5%
NP40) for 1 h at 4 °C on a rotating platform. Beads were then washed
4 times in IVT buffer before adding 25 μl SDS reducing buffer to each
sample ready for analysis by SDS-PAGE and autoradiography.
2.5. ERK activation assay
HEK-293 cells were transfected, serum starved and treatedwith EGF
as indicated. Harvesting was achieved by washing the cells with cold
PBS and adding 200 μl SDS reducing buffer directly to each well. 50 μl
of each sample was run on an SDS-PAGE gel to blot for levels of
phospho- and total ERK. Films were scanned using a GS800 densitome-
ter and bands were quantiﬁed using Quantity One. After subtraction of
background, ERK activation was calculated by dividing intensity values
for phospho-ERK by total ERK for each sample.
2.6. VSMC isolation, culture and nucleofection
VSMCs were isolated from rat aortas by enzymatic dissociation as
previously described [27]. Cells were maintained at 37 °C, with 5% CO2
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mine, 10% FCS (Gibco), penicillin 100 IU/ml/streptomycin 100 ug/ml)
was changed every 3 days. The indicated concentrations of anti-GRK2
(si)RNA (5′-GCAGGUACCUCCAGAUCUCtt-3′) (Applied Biosystems) or
scrambled control were nucleofected using Amaxa Biosystems primary
smooth muscle cell nucleofection kit and nucleofector according to the
manufacturer's instructions.
2.7. Thymidine incorporation
NucleofectedVSMCs in 12-well plateswere serum starved and treat-
ed in the presence of [3H]-thymidine (PerkinElmer) as indicated. Cells
were lysed in 1 ml 1% SDS and transferred to pyrex tubes. 2 ml PBS
was used to wash out wells and transferred to tubes. After addition of
3 ml ice cold 15% TCA (VWR), the tubes were vortexed and incubated
on ice for 5 min. Samples were then ﬁltered through pre-wetWhatman
ﬁlter paper before washing the ﬁlter paper with 20 ml ice cold 5% TCA.
Dried ﬁlters were then transferred to scintillation vials with addition of
6 ml Ultima Gold scintillation ﬂuid (PerkinElmer). Incorporated [3H]-
thymidinewas counted for 4 min using a Packard Tri-Carb liquid scintil-
lation analyzer.
3. Results
3.1. RhoAGTP is a novel binding partner for GRK2
We identiﬁed RhoAGTP as a novel binding partner for GRK2 by
performing co-immunoprecipitation experiments in COS cells. Myc-
tagged small GTPase constructs were expressed with or without GRK2
co-expression. GRK2 co-immunoprecipitatedwith RhoA-V14 (amutant
that mimics the active, GTP-bound form of RhoA) but not with RhoA-
N19 (a mutant mimicking the inactive, GDP-bound form) (Fig. 1A).
GRK2 also failed to interact with constitutively active mutants of Rac
(Rac-Q61L) and Cdc42 (Cdc42-Q61L) of the Rho GTPase superfamily+   -   +   -   +   -   +   -   +   -   +   -   +GRK2
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resentatives from 3 separate experiments.and constitutively active mutants of other small GTPases (Arf6-Q67L
and Ras-V12) (Fig. 1A). Thus, GRK2 appears to interact speciﬁcally
with active RhoA. Further co-immunoprecipitation experiments with
HA-tagged constitutively active mutants of RhoA, RhoB and RhoC indi-
cate that GRK2 binding is common to the RhoABC subfamily of Rho
GTPases (Fig. 1B). Despite different cellular functions of RhoA, B and C,
known Rho effectors, including PKN, commonly bind to all three Rho
isoforms [28]. We also observe co-immunoprecipitation of GRK2
with RhoA-V14 in β-arrestin knockout MEFs (Fig. 1C), indicating that
the interaction between these two proteins occurs independently of
β-arrestins and is not cell type speciﬁc. RhoA-V14/F25N is a stabilized
mutant of RhoA originally designed to aid in its puriﬁcation. Thismutant
binds normally to most RhoA effectors, including PKN, mDia and Rho-
associated kinase (ROCK) but is impaired in its binding to some effectors
such as diacylglycerol kinase θ (DGKθ) [22]. GRK2 binds poorly to RhoA-
V14/F25N (Fig. 1D) suggesting that GRK2 may belong to a ‘DGKθ class’
of Rho effectors. Rho binding by DGKθ is mediated by its C-terminal
152 amino acid accessory domain [22] however, the residues required
for Rho binding have not been deﬁnitively mapped.
In order to identify which region of GRK2 is responsible for RhoGTP
binding, we co-expressed tagged constructs of the amino-terminal do-
main, amino acids 45–178 (GFP-NT), catalytic domain 185–543 (CAT-
Flag) and carboxyl-terminal domain 492–689 (GST-CT) of GRK2 with
Myc-tagged RhoA-V14 in COS cells. CAT-Flag [21], GFP-NT [16] and
GST-CT [16], have previously been shown to fold and function normally
in cells (see Materials Section for full list of construct sources and refer-
ences). As assessed by co-immunoprecipitation, the catalytic domain of
GRK2 exhibits the strongest interaction with RhoA-V14 (Fig. 2A, top
panel), conﬁrming that GRK2 binds to RhoGTP, at least in part, via its cat-
alytic domain. Quantifying the amount of GRK2 co-immunoprecipitated
per unit of RhoA-V14 immunoprecipitated reveals that the catalytic
domain of GRK2 binds three times better than the full-length GRK2 con-
struct (3.0 ± 0.4 fold, P b 0.01) suggesting that, in vivo, a conformation-
al change in GRK2may be required to expose theGRK2 catalytic domainR
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the carboxyl terminus (CT) of GRK2 is poor, its interaction with the
amino terminus (NT) of GRK2 is as strong aswith the full-length kinase,indicating that the amino-terminal domain of GRK2may also contribute
to RhoA-V14 binding (Fig. 2A and B).
GRK2 is known to interact with Arf6 indirectly via GRK-interacting
protein (GIT1) [29]. That GRK2 co-immunoprecipitates with RhoA-
V14, but fails to do sowith Arf6-Q67L (Fig. 1A),may indicate that the in-
teraction between GRK2 and RhoGTP is direct. To test this, we performed
GST pull-down experiments with a GST-RhoA-V14 fusion protein or a
GST negative control (Fig. 2C). The puriﬁed fusion proteins were incu-
bated with in vitro-translated [35S]-methionine-labelled GRK2 or the
GRK2 catalytic domain (amino acids 185–543). In vitro-translated
GRK2 and GRK2 catalytic domain both bound to GST-RhoA-V14 but
not to GST (Fig. 2C). Taken together, these results indicate that GRK2 in-
teracts directly with RhoGTP via its catalytic domain, supporting a novel
role for GRK2 as a Rho effector.
3.2. RhoAGTP binding to GRK2 promotes GRK2/Raf1, GRK2/MEK1 and
GRK2/ERK2 complex formations
Co-expression of RhoA-V14 with GRK2 in COS cells or treatment of
GRK2-transfected cells with the RhoABC inhibitor C3 had no effect on
GRK2-mediated desensitisation of inositol trisphosphate production
downstream of the angiotensin receptor, as assessed by measuring
[3H]-inositol incorporation into inositol phosphates in response to
angiotensin II (ANGII) (data not shown). Similarly, GRK2-mediated rho-
dopsin phosphorylation was unaffected by RhoA-V14 co-expression, as
assessed by in vitro kinase assays using cell lysates expressing GRK2
with or without RhoA-V14 co-expression (data not shown). Since
RhoA-V14 does not appear to effect the classical role of GRK2 in
phosphorylating and desensitising GPCRs, we looked to see whether
RhoA-V14 binding to GRK2 affects its ability to interact with any of
its previously identiﬁed non-receptor binding partners. To do this,
GRK2 was co-expressed in COS cells with four such binding partners;
phosphoinositide 3-kinase (PI3Kγ); MEK1; Gq or GIT1 [2]. Under our
experimental conditions GRK2 co-immunoprecipitated with PI3Kγ,
GIT1 and Gq but not with MEK1 (Fig. 3A, B, C and D). Upon co-
expression of RhoA-V14, the co-immunoprecipitation of GRK2 with
PI3Kγ, GIT1 and Gq was equivalent to that seen in the absence of
RhoA-V14 expression, indicating that RhoA does not affect GRK2
binding to these binding partners (Fig. 3A, B and C). In marked con-
trast, co-immunoprecipitation of GRK2 with MEK1 was strongly po-
tentiated by co-expression of RhoA-V14 (Fig. 3D), suggesting that
RhoA-V14 binding to GRK2 acts to promote GRK2 binding to MEK1.
ERK scaffold proteins bind to two or more of the components of the
ERK MAPK cascade in order to promote their phosphorylation and
hence regulate the strength, duration and/or subcellular localisation of
ERK activation. This is important to regulate the speciﬁcity of cellular re-
sponses downstream of ERK. We therefore wanted to test whether
GRK2 could also bind to the upstream MAPKKK Raf and/or the down-
stream MAPK ERK. As for MEK1, co-immunoprecipitation of GRK2
with Raf1 or ERK2 is potentiated by co-expression of RhoA-V14
(Fig. 3E and F). While MEK1 [30] and ERK [31] are previously
characterised as binding partners for GRK2, the observed interaction
with Raf1 has not previously been shown. Thus, RhoA-V14 expression
promotes the interaction of GRK2 with all 3 components of the Raf/
MEK/ERK MAP kinase cascade. These results suggest that GRK2 may
have a novel function as a Rho-activated ERK MAPK scaffold protein.
That GRK2 binding to MEK1 is a direct consequence of RhoAGTP
binding to GRK2 is indicated by the following observations. Firstly,
GRK2 interacts speciﬁcally with the active mutant of RhoA, RhoA-V14,
but not with the inactive mutant, RhoA-N19 (Fig. 1A). Consistent
with this observation RhoA-V14, but not RhoA-N19, potentiates co-
immunoprecipitation of GRK2 with MEK1, when overexpressed in
COS cells (Fig. 4A). Furthermore, RhoA-V14/F25N, a mutant of RhoA-
V14 that does not interact with GRK2 (Fig. 1D) but interacts normally
with most other effectors, including ROCK [22], also fails to promote
binding of GRK2 to MEK1 (Fig. 4B). Thus RhoAGTP-dependent binding
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to GRK2 rather than an indirect consequence of RhoA signalling. Taken
together, these results support a novel function for GRK2 as a Rho effec-
tor that binds Raf1, MEK1 and ERK2 in response to RhoAGTP binding in
COS cells.
In order to test downstream of which receptors Rho-mediated Raf/
MEK/ERK binding by GRK2 may occur, we next treated COS cells with
a variety of agonists and looked to see if any affected the interaction be-
tweenGRK2 andRhoA-V14.We found that the co-immunoprecipitation
of GRK2 with RhoA-V14 is 2.0 ± 0.5 fold greater in cells treated with
EGF, relative to untreated cells (Fig. 4C top panel, 4th and 5th lane and
quantiﬁed in 4D). This is also the case for kinase dead GRK2 (GRK2-
K220R), which interacts 2.5 ± 0.7 fold more strongly with RhoA-V14
in cells treated with EGF relative to untreated cells (Fig. 4C top panel,
6th and 7th lane and quantiﬁed in 4D). Thus, EGF treatment of
COS cells promotes RhoA-V14/GRK2 complex formation, in a kinase-
independent manner, suggesting that Rho-mediated ERK scaffolding
by GRK2 might occur downstream of the EGFR.
3.3. GRK2 promotes ERK activation downstream of the EGFR by acting as a
Rho-dependent scaffold protein
Overexpression of GRK2 in HEK-293 cells has previously been
shown to potentiate ERK activation downstream of the EGFR [10,11].
Since agonist occupancy of the EGFR also activates Rho [32] and we
have found that EGF treatment promotes the interaction between
GRK2 and RhoA-V14 (Fig. 4C and 4D), we investigated whether Rho-
activated ERK scaffolding by GRK2 may, at least in part, account for
the GRK2-mediated increase in EGF-induced ERK activation that has
been reported in these cells. Consistent with previously published re-
sults [10,11], we ﬁnd that overexpression of GRK2 in HEK-293 cells re-
sults in a ~2-fold increase in EGF-induced ERK activation, as detected
by Western blotting for phospho-ERK (Fig. 5A and B). ExogenousGRK2 does not however affect the overall time course of ERK activation;
phospho-ERK levels peak at 2–5 min and return to basal levels after
10 min in both control and transfected cells (Fig. 5B). The GRK2-
mediated increase in ERK activation in response to EGF in these cells is
abolished by pretreatment with the RhoABC inhibitor C3 (Fig. 5C).
Thus GRK2-dependent ERK activation downstream of the EGFR appears
to be Rho-dependent.
If GRK2 acts as a Rho-activated ERK scaffold downstream of the EGFR,
then we would expect to observe the association of GRK2 with endoge-
nous activated P-ERK following EGF treatment. Indeed, immunoprecipi-
tation of Flag-tagged wildtype or kinase dead (K220R) GRK2 from cells
treatedwith EGF for 5 min reveals the presence of endogenous activated
ERK within the immunoprecipitates (Fig. 5D). This result suggests that
GRK2 functions as an ERK scaffold in a kinase-independent fashion. The
amount of endogenous activated ERK that co-immunoprecipitates with
overexpressed GRK2 in response to EGF treatment is increased by co-
expression of RhoA-V14 (Fig. 5E), providing further evidence that ERK
scaffolding by GRK2 is RhoAGTP-dependent. Finally, we ﬁnd that, in re-
sponse to EGF treatment, we can detect an interaction between endoge-
nous GRK2 and endogenous activated ERK (Fig. 5F), demonstrating that
this function of GRK2 is not an artefact of its overexpression. Taken to-
gether, these results suggest that Rho-activated ERK scaffolding by
GRK2 can function to increase EGF-induced ERK activation in HEK-293
cells.
3.4. GRK2 is required for EGF-induced proliferation of VSMCs
Several studies have linked increased levels of GRK2with hyperten-
sion in both patients and animal models [18]. Transgenic mice with
GRK2 speciﬁcally overexpressed in their VSMCs have increased blood
pressure associated with vascular thickening and eventually die of
heart failure [33]. Aberrant EGFR signalling [34], Rho activity and Rho
expression levels [35] have also been linked to hypertension. We thus
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we have demonstrated in HEK-293 cells might function downstream
of the EGFR in VSMCs.
We cultured VSMCs from rat aortas and performed thymidine incor-
poration experiments to measure EGF-induced VSMC proliferation.
Treatment with EGF or serum for 24 h results in, respectively, a ~2
and ~3-fold increase in thymidine incorporation relative to untreated
cells (Fig. 6A). Pre-treatment of VSMCs with the RhoABC inhibitor C3
or with the MEK1 inhibitor PD184352 resulted in 49 ± 13% and
62 ± 6.2% respective reductions in thymidine incorporation, indicating
that VSMC proliferation is, at least in part, Rho and ERK dependent
(Fig. 6B). Nucleofection of siRNA to GRK2 typically resulted in a ~70% re-
duction in GRK2 levels (Fig. 6C inset). EGF-induced thymidine incorpo-
ration in VSMCs depleted of GRK2was reduced by 59 ± 12% relative to
cells nucleofected with a scrambled control (Fig. 6C), indicating that
GRK2 is also required for EGF-induced proliferation of VSMCs. We can-
not detect GRK3 in these cells by Western blot (data not shown). This
togetherwith the observation that theMEK inhibitor and speciﬁc deple-
tion of GRK2 produce a similar percentage inhibition of EGF-dependent
thymidine incorporation suggests a speciﬁc role for GRK2, and not other
GRKs, in EGFR and ERK-dependent thymidine incorporation in this
model system. Taken together, this data demonstrates that GRK2, Rho
and ERK are all required for VSMC proliferation in response to EGF, con-
sistent with a role for Rho-activated ERK scaffolding by GRK2 down-
stream of the EGFR in VSMCs.4. Discussion
We have identiﬁed a novel function for GRK2 as a Rho effector.
Activated RhoA, which binds directly to the catalytic domain of
GRK2, promotes the interaction of GRK2 with Raf1, MEK1 and
ERK2, suggesting that GRK2 acts as a RhoA-activated ERKMAPK scaf-
fold. Consistent with this hypothesis and in agreement with previ-
ously published data [10], we ﬁnd that overexpression of GRK2
results in increased EGF-induced ERK activation. We show that this
effect of GRK2 is Rho-dependent and that EGF treatment promotes
the interaction between GRK2 and RhoGTP and between GRK2 and
P-ERK, in a kinase-independent fashion. Previously, EGF-mediated
ERK activation was shown to be potentiated in HEK-293 cells by
over-expression of phosphodiesterase-γ (PDEγ), a GRK2 substrate
[36]. GRK2-mediated PDEγ phosphorylation in response to EGF can
increase ERK activation by promoting the formation of a signalling
complex containing GRK2 and Src [11]. In light of the kinase-
independent ERK scaffolding function for GRK2 reported herein, we
can conclude that GRK2 is able to potentiate EGF-mediated ERK acti-
vation by both kinase-dependent and independent mechanisms.
The Raf kinase inhibitor protein (RKIP) can inhibit the kinase activity
of either Raf1 or GRK2 depending on its phosphorylation and
oligomerisation state [37]. PKC phosphorylation of RKIP, and consequent
dimerisation, dissociates RKIP from Raf1 and promotes binding to GRK2.
This increases receptor-stimulated ERK activity due to disinhibition of
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[37,38]. It remains to be determined whether the kinase-independent
ERK scaffolding function of GRK2 thatwe have described operates follow-
ing RKIP binding andwhether this contributes to the enhanced ERK activ-
ity observed following RKIP-mediated inhibition of GRK2 kinase activity.
β-arrestins, which function in concert with GRKs to desensitise
GPCRs, are well-characterised MAPK scaffold proteins. GRK2-mediated
and β-arrestin2-mediated scaffolding of the ERK MAPK cascade differs
in several aspects. Firstly, the ability of GRK2, but not β-arrestin2, to
bind components of the ERK cascade is stimulus (RhoAGTP)-dependent.
Secondly, GRK2-dependent ERK activation is rapid and transient
(Fig. 5A and 5B), [10] whilst β-arrestin tends to promote sustained
ERK activation [39]. Finally, β-arrestin scaffolding biases ERK towards
its cytosolic substrates [40]. In VSMCs, GRK2 is required for EGF-
induced thymidine incorporation, suggesting that ERK scaffolding by
GRK2 may be important for nuclear rather than cytosolic functions of
ERK. We are currently investigating the precise subcellular localisation
of ERK activated downstream of GRK2.
Like GRK2, connector enhancer of KSR-1 (CNK1) also appears to
function in a Rho-dependent manner. CNK1 is a scaffold protein that
can regulate a number of different signalling pathways including PI3K/
Akt activation, Src-mediated Raf1 activation and JNK MAPK signalling[41]. It has been identiﬁed as a target of Rho and it seems that binding
of active Rho by CNK1 speciﬁcally mediates its scaffolding of the JNK
MAPK cascade [42]. Thus it appears that CNK1 and GRK2 both use bind-
ing to active Rho to selectively regulate MAPK activation versus their
other signalling functions.
GRK2 can in fact regulate ERK signalling in a number of different
ways. In keeping with its classical role in GPCR desensitisation it nega-
tively regulates ANGII-induced ERK activation by phosphorylating and
promoting internalisation of the receptor in HEK-293 cells [43] and
in vivo [33]. It also co-immunoprecipitates with MEK [30] and various
groups have suggested that sequestration of MEK by GRK2 is responsi-
ble for negative regulation of chemokine-mediated ERK activation
[44,45]. Similarly, by binding and sequestering NFκB1p105, GRK2 can
negatively regulate IKKβ- and TPL2-mediated ERK activation in re-
sponse to lipopolysaccharide in mouse peritoneal macrophages [46].
Conversely, as well as downstream of EGF, GRK2 has also been shown
to promote ERK activation downstream of sphingosine 1-phosphate in
migrating epithelial cells by recruiting GIT, which in turn is proposed
to activate MEK by scaffolding Rac/PAK/MEK [47].
Clearly GRK2 has a highly complex role in regulating MAPK signal-
ling, as well as other signalling pathways, in both positive and negative
ways. How such a multifunctional protein can achieve signalling
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Fig. 6. GRK2 is required for EGF-induced proliferation of VSMCs. (A) VSMCs were serum
starved for 24 h and treatedwith EGF (10 ng/ml) or serum (10%) for 24 h in the presence
of [3H]-thymidine (3 uCi/ml). (B) After 24 h serum starving, cells were treated with EGF
(10 ng/ml) for a further 24 h in the presence of [3H]-thymidine (3 uCi/ml) with or with-
out pre-treatment with the MEK inhibitor PD184352 (1 uM) or the Rho inhibitor C3
(0.5 uM). (C) VSMCs were nucleofected or not with GRK2 siRNA or scrambled control
(100 nM). After 24 h the cells were serum starved for 24 h and then treated with EGF
(10 ng/ml) for a further 24 h in the presence of [3H]-thymidine (3 uCi/ml) After 24 h
EGF treatment, cells were harvested and counted for incorporation of [3H]-thymidine.
Fold increase in [3H]-thymidine incorporation is plotted as a percentage of scrambled con-
trol in (B) or untreated control in (C). Error bars represent standard deviation from the
mean of 3 separate experiments, statistical signiﬁcance was assessed using the two-
sample Student's t-test, *P b 0.01.
2838 J.D. Robinson, J.A. Pitcher / Cellular Signalling 25 (2013) 2831–2839speciﬁcity downstream of different agonists or in different cell types is
an interesting and poorly understood issue. Here we ﬁnd that, like
CNK1, GRK2 achieves speciﬁcity for ERK scaffolding by binding to active
Rho, suggesting that ERK scaffolding by GRK2 may occur speciﬁcally
downstream of receptors that activate Rho. In reality, however, the
mechanisms of signalling speciﬁcity downstream of GRK2 are likely
more complex. For example, while over-expression of GRK2 in HEK-
293 cells results in increased EGF-induced ERK activation, as previously
described, ERK activation in response to ANGII, which also activates Rho,
is inhibited by GRK2 over-expression in these cells [43]. Given that
RhoA-V14 interacts with the catalytic domain of GRK2 three times
more strongly than with full length GRK2, it is likely that a conforma-
tional change is required to expose the catalytic domain of GRK2 for
full RhoGTP binding in vivo. Therefore ERK scaffolding by GRK2 may
occur downstream of receptors that both activate Rho and somehow
modify GRK2 in order to expose its catalytic domain. GRK2 is a known
EGFR substrate [48] suggesting one potential mechanism whereby the
speciﬁcity of the Rho-dependent ERK scaffolding function of GRK2
may be regulated.5. Conclusions
GRK2 is a novel Rho effector that interacts speciﬁcally and directly
with active RhoA via its catalytic domain. In response to RhoAGTP bind-
ing, GRK2 binds to Raf1, MEK1 and ERK2. GRK2 promotes ERK activa-
tion in a Rho-dependent manner downstream of the EGFR and
binding of both RhoA and phospho-ERK by GRK2 is increased in re-
sponse to EGF treatment. Thus, RhoA-activated ERK scaffolding by
GRK2 functions to promote ERK activation downstream of the EGFR.
GRK2, Rho and ERK are all required for EGF-induced proliferation of
VSMCs, consistent with a role for this novel scaffolding function of
GRK2 in the vasculature.Acknowledgements
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